Evidence map›Paper›PMID 26007739›Full record

ArticleSensors (Basel, Switzerland)2015

A Highly Sensitive Porous Silicon (P-Si)-Based Human Kallikrein 2 (hK2) Immunoassay Platform toward Accurate Diagnosis of Prostate Cancer.

Sang Wook Lee, Kazuo Hosokawa, Soyoun Kim, Ok Chan Jeong, Hans Lilja, Thomas Laurell, Mizuo Maeda

Open access · goldAbstract read
In one paragraph

Article in Sensors (Basel, Switzerland), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Prostate cancer markers: An update.Biomedical reports · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 6 countries.

Sang Wook LeeBioengineering Laboratory, RIKEN, Saitama 3510198, Japan. SangWook_L@chem.s.u-tokyo.ac.jp.
Kazuo HosokawaBioengineering Laboratory, RIKEN, Saitama 3510198, Japan. k-hoso@riken.go.jp.
Soyoun KimDepartment of Biomedical Engineering, Dongguk University, Seoul 100715, Korea. skim@dongguk.edu.
Ok Chan JeongDepartment of Mechanical Engineering, Inje University, Gimhae-si 621-749, Korea. memsoku@inje.ac.kr.
Hans LiljaDepartment of Translational Medicine, Lund University, Skåne University Hospital in Malmö, Malmö 20502, Sweden. liljah@mskcc.org.
Thomas LaurellDepartment of Biomedical Engineering, Dongguk University, Seoul 100715, Korea. thomas.laurell@bme.lth.se.
Mizuo MaedaBioengineering Laboratory, RIKEN, Saitama 3510198, Japan. mizuo@riken.jp.
RIKEN · JPDongguk University · KRInje University · KRLund University · SETampere University · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Levels of total human kallikrein 2 (hK2), a protein involved the pathology of prostate cancer (PCa), could be used as a biomarker to aid in the diagnosis of this disease. In this study, we report on a porous silicon antibody immunoassay platform for the detection of serum levels of total hK2. The surface of porous silicon has a 3-dimensional macro- and nanoporous structure, which offers a large binding capacity for capturing probe molecules. The tailored pore size of the porous silicon also allows efficient immobilization of antibodies by surface adsorption, and does not require chemical immobilization. Monoclonal hK2 capture antibody (6B7) was dispensed onto P-Si chip using a piezoelectric dispenser. In total 13 × 13 arrays (169 spots) were spotted on the chip with its single spot volume of 300 pL. For an optimization of capture antibody condition, we firstly performed an immunoassay of the P-Si microarray under a titration series of hK2 in pure buffer (PBS) at three different antibody densities (75, 100 and 145 µg/mL). The best performance of the microarray platform was seen at 100 µg/mL of the capture antibody concentration (LOD was 100 fg/mL). The platform then was subsequently evaluated for a titration series of serum-spiked hK2 samples. The developed platform utilizes only 15 µL of serum per test and the total assay time is about 3 h, including immobilization of the capture antibody. The detection limit of the hK2 assay was 100 fg/mL in PBS buffer and 1 pg/mL in serum with a dynamic range of 106 (10(-4) to 10(2) ng/mL).

Indexed as

Biomarkers, TumorEquipment DesignHumansImmunoassayMaleMicroarray AnalysisPorosityProstatic NeoplasmsSiliconTissue KallikreinsBiomarkers, TumorSiliconTissue Kallikreinsantibody microarrayshuman kallikrein 2porous siliconprostate cancer

Identifiers

PMID26007739
PMCPMC4481930
OpenAlexW2137278581

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.